Results 181 to 190 of about 824,117 (206)

HIV-V3Augur: A Novel Machine Learning Model for Predicting HIV-1 Tropism in Sub-Subtype A6 and CRF63_02A6, Predominant Variants in Russia and Countries of the Former Soviet Union. [PDF]

Viruses
Elfimov K, Gotfrid L, Nokhova A, Gashnikova M, Ekushov V, Halikov M, Osipova I, Baboshko D, Murzin A, Kondeikin I, Kiryakina A, Totmenin A, Agaphonov A, Gashnikova N.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction.

Cancer Letters, 2020
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease, and novel therapeutic strategies are urgently needed. Recently, expression of the C-C chemokine receptor 5 (CCR5) and its ligands has been found to play an important role in cancer ...
Hui-ying Huang, M. Zepp, Rania B. Georges, M. Jarahian, M. Kazemi, E. Eyol, M. Berger   +6 more
semanticscholar   +1 more source

Nasal-to-brain delivery of CCR5 antagonist for reshaping the dysregulated microglia-neuron axis and enhancing post-traumatic cognitive function

Biomaterials
The dysregulation of the microglia-neuron axis plays a pivotal role in the pathogenesis of cognitive dysfunction following traumatic brain injury (TBI).
Xu Jin, Fang Luo, Dunwan Zhu
exaly   +2 more sources

DAPTA, a C‐C chemokine receptor 5 (CCR5) antagonist attenuates immune aberrations by downregulating Th9/Th17 immune responses in BTBR T+ Itpr3tf/J mice

European Journal of Pharmacology, 2019
&NA; Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder characterized by deficits in social interaction, communication, and repetitive behaviors. BTBR T+ Itpr3tf/J (BTBR) mice, a preclinical autistic model featuring ASD symptoms as
S. Ahmad, M. A. Ansari, A. Nadeem, S. Bakheet, M. Alotaibi, A. Alasmari, Musaad A. Alshammari, H. Al-Mazroua, S. Attia   +8 more
semanticscholar   +1 more source

Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells

European Journal of Immunology
Cenicriviroc, a dual CCR2/CCR5 antagonist, initially developed as an anti‐HIV drug, has shown promising results in nonalcoholic steatohepatitis phase 2 clinical trials.
Upasna Madan, Bhawna Verma, Amit Awasthi
semanticscholar   +1 more source

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist

Bioorganic and Medicinal Chemistry Letters, 2011
Swamy Yeleswaram, Maryanne Covington, Sharon Diamond   +2 more
exaly   +2 more sources

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents

European Journal of Medicinal Chemistry, 2012
Yan Zhang, Christopher K Arnatt, Kendra M Haney   +2 more
exaly   +2 more sources

CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis

Journal of Gastroenterology and Hepatology
Cenicriviroc (CVC) is a CCR2/CCR5 antagonist that has been shown to be effective in the treatment of inflammatory and fibrotic diseases. Our study evaluated its efficacy in colitis.
Xin Song, Chensheng Jiang, Mengli Yu, Chao Lu, Xinjue He   +4 more
semanticscholar   +1 more source

Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

Antiviral Research, 2014
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5
Alonso Heredia, Robert R. Redfield, Olga Latinovic   +2 more
exaly   +2 more sources

CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant*

Journal of Biological Chemistry, 2012
Background: Maraviroc-resistant HIV-1 posts challenges to CCR5 antagonist discovery. Results: CCR5 antagonist TD-0680 employs a novel mechanism for subnanomolar potency against HIV-1 entry, cell-mediated infection, and a TAK-779/Maraviroc-resistant ...
Allen K L Cheung, Zhiwei Chen, Terrence Chi-Kong Lau   +2 more
exaly   +2 more sources